Gene

CCDC6

coiled-coil domain containing 6

Explore in graph →CI-GENE-00032500HGNC:18782 ENSG00000108091 NCBI 8030 Cancer geneApproved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CCDC6 Fusion1
Futibatinib	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11646 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic
CCDC6 Fusion + TACC3 FusionTACC3 CCDC61
Erdafitinib	Adrenal CarcinomaUNRESOLVED	Predictive	C	Supports Sensitivity Response	3	accepted	EID4861

Cohorts

Alteration frequency by cohort (3)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Breast Invasive Carcinoma (British Columbia, Nature 2012) brca_bccrc	Invasive Breast Carcinoma	Ssm	2	65

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
· J Clin Oncol · 2015 · PMID 26324363 · validated civic_curation pubmed